JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares stock (ZJYL) is currently trading at $1.94. JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares PE ratio is 194.00. JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares PS ratio (Price-to-Sales) is 14.68. WallStSmart rates ZJYL as Sell.
- ZJYL PE ratio analysis and historical PE chart
- ZJYL PS ratio (Price-to-Sales) history and trend
- ZJYL intrinsic value — DCF, Graham Number, EPV models
- ZJYL stock price prediction 2025 2026 2027 2028 2029 2030
- ZJYL fair value vs current price
- ZJYL insider transactions and insider buying
- Is ZJYL undervalued or overvalued?
- JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares financial analysis — revenue, earnings, cash flow
- ZJYL Piotroski F-Score and Altman Z-Score
- ZJYL analyst price target and Smart Rating
JIN MEDICAL INTERNATIONAL
📊 No data available
Try selecting a different time range
ZJYL Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)
ZJYL trades 127% above its Graham fair value of $0.07, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL) Areas to Watch (8)
Revenue declining -16.50%, a shrinking business
Earnings declining -32.00%, profits shrinking
Very low returns on shareholder equity
Very thin margins with limited operational efficiency
Very expensive at 14.7x annual revenue
Very low institutional interest at 0.29%
Thin profit margins with limited profitability
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL) Detailed Analysis Report
Overall Assessment
This company scores 27/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 1 register as strengths (avg 10.0/10) while 8 fall into concern territory (avg 2.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.55) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Revenue Growth, EPS Growth, Return on Equity. Some valuation metrics including Price/Sales (14.68) suggest expensive pricing. Growth concerns include Revenue Growth at -16.50%, EPS Growth at -32.00%, which may limit upside. Profitability pressure is visible in Return on Equity at 4.75%, Operating Margin at 9.83%, Profit Margin at 5.76%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 4.75% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -16.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Revenue Growth and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ZJYL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ZJYL's Price-to-Sales ratio of 14.68x trades 188% above its historical average of 5.09x (71th percentile), historically expensive. The current valuation is 7% below its historical high of 15.82x set in Mar 2026, and 1568% above its historical low of 0.88x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~1.1x, reflecting growing market expectations outpacing revenue growth.
Compare ZJYL with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares operates as a stable business with moderate growth and solid fundamentals. Revenue reached 21M with 17% decline year-over-year. Profit margins are thin at 5.8%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Revenue contracted 17% YoY. Worth determining whether this is cyclical or structural.
ROE of 4.8% suggests the company isn't efficiently converting equity into profits.
What to Watch Next
Margin expansion: can JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares push profit margins above 15% as the business scales?
Valuation compression risk at a P/E of 194.0x. Any growth miss could trigger a sharp correction.
Volatility is elevated with a beta of 9.47, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares.
Bottom Line
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 11:52:46 AM
About JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares(ZJYL)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Jin Medical International Ltd. designs and manufactures wheelchairs and living aids products.